Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226048831> ?p ?o ?g. }
- W4226048831 endingPage "718" @default.
- W4226048831 startingPage "718" @default.
- W4226048831 abstract "Personalized treatment based on driver molecular alterations, such as ALK rearrangement, has revolutionized the therapeutic management of advanced oncogene-addicted NSCLC patients. Multiple effective ALK tyrosine kinase inhibitors (TKIs), with the amelioration of the activity at central nervous system level, are now available, leading to substantial prognosis improvement. The exposure to TKIs triggers resistance mechanisms and the sequential administration of other TKIs and chemotherapy is, for the most part, not targeted. In this context, extending the benefit deriving from precision medicine is paramount, above all, when disease progression occurs in a limited number of sites. Retrospective data indicate that, in oligoprogressive disease, targeted therapy beyond progression combined with definitive local treatment of the progressing site(s) is an effective alternative. In these cases, a multidisciplinary approach becomes essential for an integrated treatment strategy, depending on the site of disease progression, in order to improve not only survival, but also quality of life. In this review we provide an updated and comprehensive overview of the main treatment strategies in cases of ALK rearranged oligoprogression, including systemic treatment as well as local therapy, and report a real-world clinical story, with the final aim of identifying the most promising management for this subset of patients." @default.
- W4226048831 created "2022-05-05" @default.
- W4226048831 creator A5001428569 @default.
- W4226048831 creator A5026153195 @default.
- W4226048831 creator A5062403027 @default.
- W4226048831 creator A5066290489 @default.
- W4226048831 creator A5070036041 @default.
- W4226048831 date "2022-01-30" @default.
- W4226048831 modified "2023-10-18" @default.
- W4226048831 title "Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements" @default.
- W4226048831 cites W1973843971 @default.
- W4226048831 cites W1973870205 @default.
- W4226048831 cites W1973947576 @default.
- W4226048831 cites W1979538859 @default.
- W4226048831 cites W2021876472 @default.
- W4226048831 cites W2030227571 @default.
- W4226048831 cites W2090615329 @default.
- W4226048831 cites W2096744050 @default.
- W4226048831 cites W2099530756 @default.
- W4226048831 cites W2139110945 @default.
- W4226048831 cites W2139483106 @default.
- W4226048831 cites W2147038864 @default.
- W4226048831 cites W2151116840 @default.
- W4226048831 cites W2295354328 @default.
- W4226048831 cites W2345612806 @default.
- W4226048831 cites W2462487545 @default.
- W4226048831 cites W2482427906 @default.
- W4226048831 cites W2507645935 @default.
- W4226048831 cites W2528370542 @default.
- W4226048831 cites W2536769127 @default.
- W4226048831 cites W2555516405 @default.
- W4226048831 cites W2581996620 @default.
- W4226048831 cites W2595046651 @default.
- W4226048831 cites W2610816290 @default.
- W4226048831 cites W2623725180 @default.
- W4226048831 cites W2624310346 @default.
- W4226048831 cites W2745107466 @default.
- W4226048831 cites W2779968386 @default.
- W4226048831 cites W2782108405 @default.
- W4226048831 cites W2796631032 @default.
- W4226048831 cites W2797685139 @default.
- W4226048831 cites W2803289473 @default.
- W4226048831 cites W2805354595 @default.
- W4226048831 cites W2890523839 @default.
- W4226048831 cites W2897086689 @default.
- W4226048831 cites W2899668190 @default.
- W4226048831 cites W2912053777 @default.
- W4226048831 cites W2944635192 @default.
- W4226048831 cites W2949987709 @default.
- W4226048831 cites W2964180500 @default.
- W4226048831 cites W2965638931 @default.
- W4226048831 cites W2966785785 @default.
- W4226048831 cites W2982075775 @default.
- W4226048831 cites W3006257197 @default.
- W4226048831 cites W3022131485 @default.
- W4226048831 cites W3030445556 @default.
- W4226048831 cites W3048441995 @default.
- W4226048831 cites W3083700256 @default.
- W4226048831 cites W3084573408 @default.
- W4226048831 cites W3101089668 @default.
- W4226048831 cites W3121108262 @default.
- W4226048831 cites W3122320153 @default.
- W4226048831 cites W3147630494 @default.
- W4226048831 cites W3173160576 @default.
- W4226048831 cites W3196750844 @default.
- W4226048831 cites W4210992155 @default.
- W4226048831 cites W4240340450 @default.
- W4226048831 doi "https://doi.org/10.3390/cancers14030718" @default.
- W4226048831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35158987" @default.
- W4226048831 hasPublicationYear "2022" @default.
- W4226048831 type Work @default.
- W4226048831 citedByCount "4" @default.
- W4226048831 countsByYear W42260488312022 @default.
- W4226048831 countsByYear W42260488312023 @default.
- W4226048831 crossrefType "journal-article" @default.
- W4226048831 hasAuthorship W4226048831A5001428569 @default.
- W4226048831 hasAuthorship W4226048831A5026153195 @default.
- W4226048831 hasAuthorship W4226048831A5062403027 @default.
- W4226048831 hasAuthorship W4226048831A5066290489 @default.
- W4226048831 hasAuthorship W4226048831A5070036041 @default.
- W4226048831 hasBestOaLocation W42260488311 @default.
- W4226048831 hasConcept C117643217 @default.
- W4226048831 hasConcept C121608353 @default.
- W4226048831 hasConcept C126322002 @default.
- W4226048831 hasConcept C143998085 @default.
- W4226048831 hasConcept C151730666 @default.
- W4226048831 hasConcept C177713679 @default.
- W4226048831 hasConcept C2776232967 @default.
- W4226048831 hasConcept C2776256026 @default.
- W4226048831 hasConcept C2779134260 @default.
- W4226048831 hasConcept C2779343474 @default.
- W4226048831 hasConcept C2781230642 @default.
- W4226048831 hasConcept C60644358 @default.
- W4226048831 hasConcept C71924100 @default.
- W4226048831 hasConcept C86803240 @default.
- W4226048831 hasConceptScore W4226048831C117643217 @default.
- W4226048831 hasConceptScore W4226048831C121608353 @default.
- W4226048831 hasConceptScore W4226048831C126322002 @default.